HeartFlow, Inc

#HeartFlow stands out from other companies because we combine advanced technology and human ingenuity. Our non-invasive personalized cardiac tests allow physicians to not only create more effective treatment plans but also combat the #1 cause of death: heart disease. Check out our new technology here and schedule a live demonstration: https://bit.ly/3rTf2uM. #CAD #yesCCT #FFRCT #CCTA

Why should you care about plaque? It’s proven that quantification and characterization of atherosclerosis provides a better path towards risk stratification. https://bit.ly/4abw4tf. #HeartFlowPlaqueAnalysis #TruePlaqueBurden #Plaque

Despite being conscious about his heart health, 60-year old Mike Gartman suddenly experienced classic symptoms of a patient with suspected #CAD. With the traditional care pathway, Mike would have had to undergo an invasive catheterization procedure. However, with the help of his #HeartFlow Analysis results, he was able to avoid the invasive procedure altogether and gain peace of mind about his disease. Read Mike's story here: https://bit.ly/3R2B5Nk.

The final video in the series about debunking common misconceptions associated with using coronary CTA to diagnose CAD is here! This one discussed radiation exposure and safety of CCTA versus traditional SPECT testing. If you would like to watch all 5 videos, please go to https://lnkd.in/gBwB2uRn. Thank you for tuning in! We would also like to give a special shout out to Payal Kohli, MD, FACC for providing such valuable education!

Key findings from the PRECISE Trial show that, when compared to traditional testing, the Precision Pathway (centered around coronary CTA + FFRct) improved non-invasive diagnostic accuracy, reduced unnecessary tests, and increased confidence in treating the right patients. Learn more about the PRECISE Trial and its results here: https://bit.ly/3IqPL4G. #HeartFlow #FFRct #CAD #AI

🎉 Happy New Year from all of us at HeartFlow! 🎉 As we step into 2025, we want to take a moment to express our deepest gratitude to our incredible team and valued partners. Your dedication, innovation, and collaboration have been the heartbeat of our success this year. Thank you for your hard work, passion, and commitment to advancing the future of cardiovascular care. Here’s to building on our achievements, embracing new opportunities, and continuing to make a difference—together. ✨ Wishing you all a happy, healthy, and prosperous New Year! ✨ 💙 Here’s to 2025! 💙

Celebrating a Year of Innovation and Impact at HeartFlow! 🎉 As we reflect on 2024, we're proud of the incredible milestones HeartFlow has achieved for patients with symptoms of coronary artery disease (CAD). This year has been one of growth, innovation, and progress as we continue our mission to transform cardiovascular care. Key milestones of 2024: 🔹 Groundbreaking CMS Reimbursement Increases: We're celebrating reimbursement progress for CCTA, FFRct and Plaque Analysis! Effective January 2025, CCTA outpatient services, HeartFlow FFRct, and AI-enabled Plaque Analysis will all see new payment rates, highlighting the growing recognition of AI-powered cardiac care to improve patient outcomes. 🔹 Advancing Plaque Analysis with the Launch of the DECIDE Registry and Interactive Plaque Analysis Platform: HeartFlow introduced an upgraded Plaque Analysis platform, fully integrated with FFRct, offering the only plaque quantification tool with lesion-specific FFRct values. The interactive, 3D model provides a comprehensive view of plaque volume across calcified, non-calcified, and low-attenuation plaque types, enabling personalized treatment plans for patients with CAD. Additionally, the launch of the DECIDE Registry will collect real-world data to further enhance clinical decision-making and patient management for HeartFlow's Plaque Analysis. 🔹 Rigorous Clinical Data backing HeartFlow Technology: Seven-year data from the ADVANCE-DK study confirmed the long-term value of HeartFlow FFRct and Plaque Analysis in assessing long-term risks, informing more personalized and effective treatment plans for patients with CAD. Happy New Year from all of us at HeartFlow and here's to a heart healthy 2025!

🎉 Huge congratulations to UMass Memorial University Campus for earning the prestigious #HeartFlow CT Quality Award! 🏆 This award recognizes medical centers that excel in the quality and adoption of cardiovascular imaging programs, specifically those using coronary CT and the HeartFlow Analysis to better assess heart health. UMass Memorial has proven to be among the top 22% of global medical centers, providing patients with a clearer, more accurate pathway to understand and manage their heart health. ❤️ We're proud to celebrate their commitment to innovation and excellence in cardiovascular care. Here's to continued success in improving patient outcomes! 🌟 UMass Memorial Medical Center #yesCCT #FFRCT #CCTA #AI

👏 Congratulations to Aurora Oshkosh! 👏 We’re excited to celebrate Aurora Oshkosh as a first-time recipient of the HeartFlow CT Quality Award for Q3 2024! This honor recognizes the top 22% of hospitals globally in cardiovascular imaging and patient care. By using coronary CT and the HeartFlow Analysis, Aurora Oshkosh is leading the way in heart health, offering patients more accurate assessments for better outcomes. Kudos to their commitment to excellence in cardiovascular care! 🫀🥇 Aurora Health Care #FFRCT #CCTA #yesCCT

The 4th video in the series debunking misconceptions around coronary CTA with Payal Kohli, MD, FACC discusses how insurance coverage for CCTA to diagnose suspected CAD may have improved recently.